Patent:

Methods of regulating cannabinoid receptor activity-related disorders and diseases

Current Assignee

US Department of Health and Human Services (HHS)

2020-01-30 Publication of US20200030261A1

Abstract

This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.

https://patents.google.com/patent/US20200030261A1/

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&d=PG01&s1=20200030261.PGNR.

>>8902775

Patent:

Compositions and methods for treating diseases and conditions

Current Assignee University of Pittsburgh US Department of Veterans Affairs

2020-03-19 Publication of US20200087294A1

What is claimed is:

1. A method for treating an inflammatory disorder comprising administering to a subject in need thereof a compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof … wherein the inflammatory disorder is selected from asthma, chronic obstructive lung disease, pulmonary fibrosis, pneumonitis, pneumonia, cystic fibrosis, psoriasis, arthritis/rheumatoid arthritis, rhinitis, pharyngitis, cystitis, prostatitis, dermatitis, allergy including hayfever, nephritis, conjunctivitis, encephalitis, meningitis, opthalmitis, uveitis, pleuritis, pericarditis, myocarditis, atherosclerosis, human immunodeficiency virus related inflammation, diabetes, osteoarthritis, psoriatic arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, sepsis, vasculitis, bursitis, connective tissue disease, autoimmune diseases such as systemic lupus erythematosis (SLE), polymyalgia rheumatica, scleroderma, Wegener's granulomatosis, temporal arteritis, vasculitis, cryoglobulinemia, and multiple sclerosis, viral or influenza-induced inflammation, or edema.

>>8902972

Patent:

Photosensitizing antibody-fluorophore conjugates

US Department of Health and Human Services (HHS)

Abstract

The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm−2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.

https://patents.google.com/patent/US20200085950A1/

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&d=PG01&s1=20200085950.PGNR.

>>8903004

Patent:

Zinc phthalocyanine and perylene co-loaded multifunctional nanoparticles for photodynamic therapy

2019-02-21

Publication of WO2019035947A1

Application filed by The Government Of The United States Of America, As Represented By The Secretary Of The Navy

Abstract

A liquid crystal nanoparticle (LCNP)-based system allows for the encapsulation and targeted delivery of Zinc (II) phthalocyanine (ZnPC) to the plasma membrane bilayer of living cells for photodynamic therapy (PDT). The formulation comprises LCNPs that are loaded in their hydrophobic core with perylene (PY) and ZnPC. In embodiments, the LCNP surface is functionalized with poIy(ethylene glycoI)-cholesteroI conjugates (PEG-Chol) and/or another material enabling targeting the particle to the cellular membrane. This can improve cell killing via reactive oxygen species (ROS) generation as it allows for the localized ROS-mediated peroxidation of lipids in the membrane bilayer.

https://patents.google.com/patent/WO2019035947A1/

>>8903061

That is what it appears to me but I'm not a brainiac.

Putting it out there for someone smarter to dig on.